Risk factors of the suprasternal lymph node metastasis in papillary thyroid carcinoma with clinical lateral cervical lymph node metastasis

Kwon, Hyun-Keun; Cheon, Yong-Il; Shin, Sung‐Chan; Sung, Eui‐Suk; Lee, Jin‐Choon; Kim, In-Ju; Lee, Byung‐Joo

doi:10.21203/rs.3.rs-17663/v1

Cited by 2 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, previous studies recommended dissecting the LNSS and SSLN in PTC patients with lateral compartment lymph node metastasis. 11,12,15,16 In addition, previous studies supported LNSS and SSLN dissection because it is a low risk and easy procedure.…”

Section: Resultsmentioning

confidence: 96%

“…12 Recently, Kwon et al reported the rate of suprasternal lymph node metastasis in PTC patients who underwent therapeutic lateral neck dissection due to clinically positive nodes in the lateral compartment as 12.9%. 16 They reported that SSLN metastasis was associated with tumors located in the inferior pole of the thyroid gland and level IV metastasis. 16 In addition, Yuan et al suggested a group of lymph nodes between the investing layer of the deep cervical fascia and the infrahyoid strap muscle fascia.…”

Section: Resultsmentioning

confidence: 99%

“…16 They reported that SSLN metastasis was associated with tumors located in the inferior pole of the thyroid gland and level IV metastasis. 16 In addition, Yuan et al suggested a group of lymph nodes between the investing layer of the deep cervical fascia and the infrahyoid strap muscle fascia. 15 This group seems to include the SSLN, LNSS, and the superficial area anterior to the larynx.…”

Section: Resultsmentioning

confidence: 99%

“…The incidence and significance of metastasis to the LNSS and SSLN have not been clearly determined, although a few studies have investigated these points 11,12,14–16 . Further, it is difficult to differentiate between LNSS and SSLN in real operations.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Occult metastasis to the superficial level VI lymph nodes in papillary thyroid carcinoma

Lee

Song

et al. 2022

Head & Neck

View full text Add to dashboard Cite

Background This study aimed to evaluate the incidence and risk factors of occult metastasis to superficial level VI, defined as the space anterior to the strap muscles, including the lymph nodes between the sternocleidomastoid and sternohyoid muscles and suprasternal space lymph nodes. Methods We studied 129 patients with papillary thyroid carcinoma who underwent thyroidectomy and neck dissection, including superficial level VI dissection. Results Of the 129 patients, 62 (48%) had lymph nodes in the harvested specimens of superficial level VI, and the mean number of lymph nodes retrieved was 1.9 ± 1.2. Occult metastasis to superficial level VI occurred in four patients (3.1%). No significant risk factors of superficial level VI occult metastasis were noted in multivariate analysis. Conclusions Occult metastasis to superficial level VI was rare in patients with papillary thyroid carcinoma. Therefore, prophylactic dissection of superficial level VI may not be necessary for primary papillary thyroid carcinoma.

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Occult metastasis to the superficial level VI lymph nodes in papillary thyroid carcinoma

Lee

Song

et al. 2022

Head & Neck

View full text Add to dashboard Cite

show abstract

“…Papillary thyroid cancer (PTC) is an endocrine malignancy that occurs in thyroid follicular cells [1]. The incidence of PTC has increased rapidly worldwide over the last 3 decades.…”

Section: Introductionmentioning

confidence: 99%

80MAP17 promotes the tumorigenesis of papillary thyroid carcinoma by reducing the stability of p53

Yu¹,

Lü²,

Chen

et al. 2021

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Background: Papillary thyroid cancer (PTC) is an endocrine malignancy whose incidence has increased rapidly worldwide. MAP17 (PDZKIP1) is a small protein related to tumor progression. The aim of this study was to investigate the role of MAP17 in PTC and the underlying molecular mechanism. Methods: Bioinformatics, Western blotting and immunohistochemistry were used to analyze the expression of MAP17 in PTC. The gene transcription was measured by qPCR. Cell viability was determined by CCK8 assay. Cell growth was measured by clonal formation assay. Cell apoptosis was measured by TUNEL. Wound healing assay and transwell assay were used to measure the mobility of cells. The expression of E-cadherin and N-cadherin was determined by immunofluorescence. The effect of MAP17 on tumor growth was determined in animal experiments. Results: The results showed that MAP17 was up-regulated in PTC, which significantly promoted the growth and motility of PTC cells, but inhibited cell apoptosis. Besides, overexpression of MAP17 accelerated cycloheximide (CHX, a protein synthesis inhibitor)-induced p53 degradation, while low expression of MAP17 slowed down CHX-induced p53 degradation, suggesting that MAP17 can regulate p53 stability. Notably, NUMB exhibited an opposite effect on P53 stability. Interestingly, p53 overexpression reversed the effects of MAP17 overexpression on cell viability, motility, and apoptosis, indicating that p53 was involved in the progression of PTC. In vivo studies have shown that tumor growth was positively correlated with MAP17 expression and negatively correlated with p53 expression. Conclusion: Our findings revealed that MAP17 exhibited carcinogenic effects through interacting with NUMB to reduce the stability of p53, demonstrating that MAP17 may serve as a potential prognostic biomarker for PTC treatment.

show abstract

Risk factors of the suprasternal lymph node metastasis in papillary thyroid carcinoma with clinical lateral cervical lymph node metastasis

Cited by 2 publications

References 22 publications

Occult metastasis to the superficial level VI lymph nodes in papillary thyroid carcinoma

Occult metastasis to the superficial level VI lymph nodes in papillary thyroid carcinoma

80MAP17 promotes the tumorigenesis of papillary thyroid carcinoma by reducing the stability of p53

Contact Info

Product

Resources

About